pre-miRNA Information | |
---|---|
pre-miRNA | hsa-mir-1268a |
Genomic Coordinates | chr15: 22225278 - 22225329 |
Description | Homo sapiens miR-1268a stem-loop |
Comment | None |
RNA Secondary Structure |
Mature miRNA Information | |||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mature miRNA | hsa-miR-1268a | ||||||||||||||||||||||||||||||||||||
Sequence | 5| CGGGCGUGGUGGUGGGGG |22 | ||||||||||||||||||||||||||||||||||||
Evidence | Experimental | ||||||||||||||||||||||||||||||||||||
Experiments | Illumina | ||||||||||||||||||||||||||||||||||||
SNPs in miRNA |
|
||||||||||||||||||||||||||||||||||||
Putative Targets |
miRNA Expression profile | |
---|---|
Human miRNA Tissue Atlas | |
miRNAs in Extracellular Vesicles |
|
Circulating MicroRNA Expression Profiling |
Gene Information | |||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Gene Symbol | CAMK2G | ||||||||||||||||||||
Synonyms | CAMK, CAMK-II, CAMKG | ||||||||||||||||||||
Description | calcium/calmodulin dependent protein kinase II gamma | ||||||||||||||||||||
Transcript | NM_001222 | ||||||||||||||||||||
Other Transcripts | NM_172169 , NM_172170 , NM_172171 , NM_172173 | ||||||||||||||||||||
Expression | |||||||||||||||||||||
Putative miRNA Targets on CAMK2G | |||||||||||||||||||||
3'UTR of CAMK2G (miRNA target sites are highlighted) |
>CAMK2G|NM_001222|3'UTR 1 GCTCAGCCACAGGGGCTTTAGGAGATTCCAGCCGGAGGTCCAACCTTCGCAGCCAGTGGCTCTGGAGGGCCTGAGTGACA 81 GCGGCAGTCCTGTTTGTTTGAGGTTTAAAACAATTCAATTACAAAAGCGGCAGCAGCCAATGCACGCCCCTGCATGCAGC 161 CCTCCCGCCCGCCCTTCGTGTCTGTCTCTGCTGTACCGAGGTGTTTTTTACATTTAAGAAAAAAAAAAAAGAAAAAAAGA 241 TTGTTTAAAAAAAAAAGGAATCCATACCATGATGCGTTTTAAAACCACCGACAGCCCTTGGGTTGGCAAGAAGGCAGGAG 321 TATGTATGAGGTCCATCCTGGCATGAGCAGTGGCTCACCCACCGGCCTTGAAGAGGTGAGCTTGGCCTCTCTGGTCCCCA 401 TGGACTTAGGGGGACCAGGCAAGAACTCTGACAGAGCTTTGGGGGCCGTGATGTGATTGCAGCTCCTGAGGTGGCCTGCT 481 TACCCCAGGTCTAGGAATGAACTTCTTTGGAACTTGCATAGGCGCCTAGAATGGGGCTGATGAGAACATCGTGACCATCA 561 GACCTACTTGGGAGAGAACGCAGAGCTCCCAGCCTGCTGTGGAGGCAGCTGAGAAGTGGTGGCCTCAGGACTGAGAGCCC 641 GGACGTTGCTGTACTGTCTTGTTTAGTGTAGAAGGGAAGAGAATTGGTGCTGCAGAAGTGTACCCGCCATGAAGCCGATG 721 AGAAACCTCGTGTTAGTCTGACATGCACTCACTCATCCATTTCTATAGGATGCACAATGCATGTGGGCCCTAATATTGAG 801 GCCTTATCCCTGCAGCTAGGAGGGGGAGGGGTTGTTGCTGCTTTGCTTCGTGTTTTCTTCTAACCTGGCAAGGAGAGAGC 881 CAGGCCCTGGTCAGGGCTCCCGTGCCGCCTTTGGCGGTTCTGTTTCTGTGCTGATCTGGACCATCTTTGTCTTGCCTTTT 961 CACGGTAGTGGTCCCCATGCTGACCCTCATCTGGGCCTGGGCCCTCTGCCAAGTGCCCCTGTGGGATGGGAGGAGTGAGG 1041 CAGTGGGAGAAGAGGTGGTGGTCGTTTCTATGCATTCAGGCTGCCTTTGGGGCTGCCTCCCTTCTTATTCTTCCTTGCTG 1121 CACGTCCATCTCTTTTCCTGTCTTTGAGATTGACCTGACTGCTCTGGCAAGAAGAAGAGGTGTCCTTACAGAGGCCTCTT 1201 TACTGACCAACTGAAGTATAGACTTACTGCTGGACAATCTGCATGGGCATCACCCCTCCCCGCATGTAACCCAAAAGAGG 1281 TGTCCAGAGCCAAGGCTTCTACCTTCATTGTCCCTCTCTGTGCTCAAGGAGTTCCATTCCAGGAGGAAGAGATCTATACC 1361 CTAAGCAGATAGCAAAGAAGATAATGGAGGAGCAATTGGTCATGGCCTTGGTTTCCCTCAAAACAACGCTGCAGATTTAT 1441 CTGCACAAACATCTCCACTTTTGGGGGAAAGGTGGGTAGATTCCAGTTCCCTGGACTACCTTCAGGAGGCACGAGAGCTG 1521 GGAGAAGAGGCAAAGCTACAGGTTTACTTGGGAGCCAGCTGAGAAGAGAGCAGACTCACAGGTGCTGGTGCTTGGATTTA 1601 GCCAGGCTCCTCCGAGCACCTCATGCATGTCCCAGCCCCTGGGCCCTAGCCCTTTCCTGCCCTGCAGTCTGCAGTGCCAG 1681 CACGCAAATCCCTTCACCACAGGGTTTCGTTTTGCTGGCTTGAAGACAAATGGTCTTAGAATTCATTGAGACCCATAGCT 1761 TCATATGGCTGCTCCAGCCCCACTTCTTAGCATTCTTACTCCTCTTCTGGGGCTAATGTCAGCATCTATAGACAATAGAC 1841 TATTAAAAAATCACCTTTTAAACAAGAAACGGAAGGCATTTGATGCAGAATTTTTGCATGACAACATAGAAATAATTTAA 1921 AAATAGTGTTTGTTCTGAATGTTGGTAGACCCTTCATAGCTTTGTTACAATGAAACCTTGAACTGAAAATATTTAATAAA 2001 ATAACCTTTAAACAGTC Target sites
Provided by authors
Predicted by miRanda
DRVs
SNPs
DRVs & SNPs
|
||||||||||||||||||||
miRNA-target interactions (Predicted by miRanda) |
|
||||||||||||||||||||
DRVs in gene 3'UTRs | |||||||||||||||||||||
SNPs in gene 3'UTRs |
Experimental Support 1 for Functional miRNA-Target Interaction | |
---|---|
miRNA:Target | ---- |
Validation Method |
|
Conditions | USSC |
Location of target site | 3'UTR |
Original Description (Extracted from the article) |
...
Table 2. Putative target genes and related pathways for miRNAs.
... - Bakhshandeh B; Soleimani M; Paylakhi SH; Ghaemi N, 2012, Journal of genetics. |
Article |
- Bakhshandeh B; Soleimani M; Paylakhi SH; Ghaemi N - Journal of genetics, 2012
Generating appropriate cartilage for clinical applications to heal skeletal tissue loss is a major health concern. In this regard, cell-based approaches offer a potential therapeutic strategy for cartilage repair, although little is known about the precise mechanism of chondrogenesis. Unrestricted somatic stem cell (USSC) is considered as a suitable candidate because of its potential for differentiating into multiple cell types. Recent studies show that microRNAs (miRNAs) are involved in several biological processes including development and differentiation. To identify the chondro-specific miRNA signature, miRNA patterns of USSCs and differentiated chondrocytes were investigated using microarrays and validation by qPCR. Prior to these analyses, chondrogenic commitment of differentiated USSCs was verified by immunocytochemistry, specific staining and evaluation of some main chondrogenic marker genes. Various in silico explorations (for both putative targets and signalling pathways) and empirical analyses (miRNA transfections followed by qPCR of some chondrogenic indicators) were carried out to support our results. Transient modulation of multiple chondro-miRs (such as mir-630, mir-624 and mir-376) with chondrocyte targets (such as TGFbR, MAP3K, collagens, SMADs and cadherins) as mediators of chondrogenic signalling pathways including cell-cell interactions, TGF-beta, and MAPK signalling suggests a mechanism for genetic induction of chondrogenic differentiation. In conclusion, this research reveals more details about the allocation of USSCs into the chondrocytes through identification of miRNA signature which modulates targets and pathways required for chondrogenic lineage and could provide guidelines for future clinical treatments and anti-miRNA therapies.
LinkOut: [PMID: 22942087]
|
MiRNA-Target Expression Profile | |||||||
---|---|---|---|---|---|---|---|
|
MiRNA-Target Expression Profile (TCGA) | |||||||
---|---|---|---|---|---|---|---|
|
44 hsa-miR-1268a Target Genes:
Functional analysis:
ID | Target | Description | Validation methods | |||||||||
Strong evidence | Less strong evidence | |||||||||||
MIRT035845 | POLR2I | RNA polymerase II subunit I | 1 | 1 | ||||||||
MIRT035847 | FASN | fatty acid synthase | 1 | 1 | ||||||||
MIRT053736 | SOX12 | SRY-box 12 | 1 | 1 | ||||||||
MIRT053737 | CAMK2G | calcium/calmodulin dependent protein kinase II gamma | 1 | 1 | ||||||||
MIRT473717 | MAPK1 | mitogen-activated protein kinase 1 | 2 | 2 | ||||||||
MIRT483654 | QSOX2 | quiescin sulfhydryl oxidase 2 | 2 | 4 | ||||||||
MIRT484277 | AIP | aryl hydrocarbon receptor interacting protein | 2 | 4 | ||||||||
MIRT486674 | WDR81 | WD repeat domain 81 | 2 | 2 | ||||||||
MIRT488672 | WWP2 | WW domain containing E3 ubiquitin protein ligase 2 | 2 | 4 | ||||||||
MIRT493453 | ITFG3 | family with sequence similarity 234 member A | 2 | 2 | ||||||||
MIRT495902 | ZNF641 | zinc finger protein 641 | 2 | 2 | ||||||||
MIRT500188 | BARX1 | BARX homeobox 1 | 2 | 4 | ||||||||
MIRT512015 | DNAJC10 | DnaJ heat shock protein family (Hsp40) member C10 | 2 | 2 | ||||||||
MIRT521134 | SGPL1 | sphingosine-1-phosphate lyase 1 | 2 | 4 | ||||||||
MIRT530047 | TRIM72 | tripartite motif containing 72 | 2 | 2 | ||||||||
MIRT531519 | NOM1 | nucleolar protein with MIF4G domain 1 | 2 | 2 | ||||||||
MIRT543736 | DHCR7 | 7-dehydrocholesterol reductase | 2 | 2 | ||||||||
MIRT558054 | EVI5L | ecotropic viral integration site 5 like | 2 | 2 | ||||||||
MIRT569603 | TRIM29 | tripartite motif containing 29 | 2 | 2 | ||||||||
MIRT570027 | FAM228A | family with sequence similarity 228 member A | 2 | 2 | ||||||||
MIRT573595 | CERS1 | ceramide synthase 1 | 2 | 2 | ||||||||
MIRT623884 | FRMPD4 | FERM and PDZ domain containing 4 | 2 | 2 | ||||||||
MIRT630000 | PDE6B | phosphodiesterase 6B | 2 | 2 | ||||||||
MIRT632716 | MSANTD4 | Myb/SANT DNA binding domain containing 4 with coiled-coils | 2 | 2 | ||||||||
MIRT633497 | ERO1L | endoplasmic reticulum oxidoreductase 1 alpha | 1 | 1 | ||||||||
MIRT637076 | SELPLG | selectin P ligand | 2 | 2 | ||||||||
MIRT638183 | TLN1 | talin 1 | 2 | 2 | ||||||||
MIRT638767 | EPB41 | erythrocyte membrane protein band 4.1 | 2 | 2 | ||||||||
MIRT668073 | GMPS | guanine monophosphate synthase | 2 | 2 | ||||||||
MIRT669874 | RAET1E | retinoic acid early transcript 1E | 2 | 2 | ||||||||
MIRT670664 | KIAA1551 | KIAA1551 | 2 | 2 | ||||||||
MIRT671283 | RPL37A | ribosomal protein L37a | 2 | 2 | ||||||||
MIRT675055 | OR7D2 | olfactory receptor family 7 subfamily D member 2 | 2 | 2 | ||||||||
MIRT682784 | BLOC1S3 | biogenesis of lysosomal organelles complex 1 subunit 3 | 2 | 2 | ||||||||
MIRT683344 | SCARF1 | scavenger receptor class F member 1 | 2 | 2 | ||||||||
MIRT690283 | ZNF154 | zinc finger protein 154 | 2 | 2 | ||||||||
MIRT695172 | SLC25A33 | solute carrier family 25 member 33 | 2 | 2 | ||||||||
MIRT695222 | SCAMP3 | secretory carrier membrane protein 3 | 2 | 2 | ||||||||
MIRT700485 | PTPRF | protein tyrosine phosphatase, receptor type F | 2 | 2 | ||||||||
MIRT700601 | PRKCA | protein kinase C alpha | 2 | 2 | ||||||||
MIRT701410 | NKRF | NFKB repressing factor | 2 | 2 | ||||||||
MIRT703995 | EIF5A2 | eukaryotic translation initiation factor 5A2 | 2 | 2 | ||||||||
MIRT711232 | RETSAT | retinol saturase | 2 | 2 | ||||||||
MIRT719510 | TMEM175 | transmembrane protein 175 | 2 | 2 |
miRNA-Drug Associations | ||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
miRNA-Drug Resistance Associations | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|